Journal of Clinical Oncology, 0732-183X

Journal

View graph of relations

Related Publications
  1. A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma

    Adams, H. J. A. & Kwee, T. C., 1-Apr-2019, In : Journal of Clinical Oncology. 37, 10, p. 852-854 3 p.

    Research output: Contribution to journalLetterAcademicpeer-review

  2. Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed

    Adams, H. J. A. & Kwee, T. C., 20-Feb-2019, In : Journal of Clinical Oncology. 37, 6, p. 525-526 2 p.

    Research output: Contribution to journalLetterAcademicpeer-review

  3. Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma

    Adams, H. J. A. & Kwee, T. C., 10-Nov-2018, In : Journal of Clinical Oncology. 36, 32, p. 3271-3273 3 p.

    Research output: Contribution to journalLetterAcademicpeer-review

  4. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score

    Cherny, N. I., de Vries, E. G. E., Dafni, U., Garrett-Mayer, E., McKernin, S. E., Piccart, M., Latino, N. J., Douillard, J-Y., Schnipper, L. E., Somerfield, M. R., Bogaerts, J., Karlis, D., Zygoura, P., Vervita, K., Pentheroudakis, G., Tabernero, J., Zielinski, C., Wollins, D. S. & Schilsky, R. L., 1-Feb-2019, In : Journal of Clinical Oncology. 37, 4, p. 336-349 15 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Reply to A. Addeo et al, H. Zeng et al, and C.G. Rusthoven

    De Ruysscher, D. K. & Groen, H. J., 1-Dec-2018, In : Journal of Clinical Oncology. 36, 34, p. 3434-+ 3 p.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

View all (298) »

ID: 1516386